Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival - PubMed (original) (raw)
doi: 10.1016/j.exphem.2003.09.021.
Ming-Sheng Lee, Rima M Saliba, Borje Andersson, Paolo Anderlini, Daniel Couriel, Chitra Hosing, Sergio Giralt, Martin Korbling, John McMannis, Michael J Keating, Richard E Champlin
Affiliations
- PMID: 14725898
- DOI: 10.1016/j.exphem.2003.09.021
Free article
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
Issa F Khouri et al. Exp Hematol. 2004 Jan.
Free article
Abstract
Objective: To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia.
Patients and methods: Patients were eligible to treatment if they were refractory or recurred after a prior response to fludarabine. Seventeen patients were treated. All patients received a preparative regimen of fludarabine (30 mg/m(2) daily for 3 days) and intravenous cyclophosphamide (750 mg/m(2) daily for 3 days). Ten patients received rituximab in addition to chemotherapy. The median time from diagnosis to transplant was 67 months. Nine of 17 patients had refractory disease.
Results: All patients had engraftment of donor cells. Eleven (65%) did not require platelet transfusions. Ten patients with persistent disease underwent immunomanipulation to augment GVL effects including immunosuppression withdrawal and donor lymphocyte infusion with or without rituximab treatment. Seven of these 10 patients had a complete response and 2 had a partial response; 8 of these 9 responders had received rituximab with their immunomanipulation process. The final response was complete remission in 12 and partial remission in 4 patients for an overall response rate of 94%. Overall survival was 100% for patients who received the combined chemo-rituximab conditioning regimen, vs 14% for those who received chemotherapy alone (p=0.03).
Conclusion: Our results indicate that a pronounced GVL effect occurs after nonmyeloablative allogeneic hematopoietic transplantation for advanced CLL. This activity might be facilitated by rituximab. Prospective controlled trials are needed to define the role of nonablative allogeneic hematopoietic transplantation for treatment of this disease.
Similar articles
- Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Khouri IF, et al. Blood. 2001 Dec 15;98(13):3595-9. doi: 10.1182/blood.v98.13.3595. Blood. 2001. PMID: 11739162 Clinical Trial. - Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Khouri IF, et al. J Clin Oncol. 1998 Aug;16(8):2817-24. doi: 10.1200/JCO.1998.16.8.2817. J Clin Oncol. 1998. PMID: 9704734 - Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.
Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Khouri IF, et al. Cancer. 2011 Oct 15;117(20):4679-88. doi: 10.1002/cncr.26091. Epub 2011 Mar 31. Cancer. 2011. PMID: 21455998 Free PMC article. - Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review. - Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005. Drugs. 2003. PMID: 12662126 Review.
Cited by
- Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.
van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP. van Gelder M, et al. Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15. Bone Marrow Transplant. 2016. PMID: 26878656 Clinical Trial. - Adoptive T-cell therapy for Leukemia.
Garber HR, Mirza A, Mittendorf EA, Alatrash G. Garber HR, et al. Mol Cell Ther. 2014 Aug 12;2:25. doi: 10.1186/2052-8426-2-25. eCollection 2014. Mol Cell Ther. 2014. PMID: 26056592 Free PMC article. Review. - Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Rozovski U, et al. J Clin Oncol. 2015 May 10;33(14):1557-63. doi: 10.1200/JCO.2014.58.6750. Epub 2015 Apr 6. J Clin Oncol. 2015. PMID: 25847930 Free PMC article. - New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.
Rein LA, Sung AD, Rizzieri DA. Rein LA, et al. Int J Hematol Oncol. 2013 Feb;2(1):10.2217/ijh.13.4. doi: 10.2217/ijh.13.4. Int J Hematol Oncol. 2013. PMID: 24303095 Free PMC article. - Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.
Wahid SF. Wahid SF. Int J Hematol. 2013 May;97(5):581-98. doi: 10.1007/s12185-013-1313-0. Epub 2013 Apr 13. Int J Hematol. 2013. PMID: 23585244 Review.